SCHEMBL136463

SCHEMBL136463

O=C(O)Cc1cc(OCc2ccccc2)cc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.56
RXRB P28702 4/20 0.56
RXRG P48443 4/20 0.56
LTB4R Q15722 2/20 0.54
LTB4R2 Q9NPC1 2/20 0.54
NR4A2 P43354 2/20 0.53
FFAR1 O14842 1/20 0.53
FFAR4 Q5NUL3 1/20 0.53
MRGPRX4 Q96LA9 2/20 0.52
PTPN2 P17706 2/20 0.51
PTPN1 P18031 2/20 0.51
PTPN6 P29350 2/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAOB P27338 3/20 0.49
PPARD Q03181 2/20 0.48
PPARA Q07869 2/20 0.48
SLC26A3 P40879 1/20 0.47
PPARG P37231 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570315 0.90 PTPN1 (0.58) RXRARXRBRXRGLTB4RLTB4R2
SCHEMBL135927 0.87 NR4A2 (0.49) RXRARXRBRXRGLTB4RLTB4R2
SCHEMBL27799862 0.86 FFAR1 (0.67) NR4A2FFAR1FFAR4MRGPRX4
SCHEMBL478042 0.86 PPARD (0.65) RXRARXRBRXRGFFAR1PTPN2
SCHEMBL9205498 0.85 LTB4R (0.68) LTB4RLTB4R2NR4A2FFAR1FFAR4
SCHEMBL2957881 0.85 MEN1 (0.67) LTB4RLTB4R2NR4A2FFAR1FFAR4
SCHEMBL136924 0.85 RXRA (0.47) RXRARXRBRXRGLTB4RLTB4R2
SCHEMBL5764984 0.84 NR4A2 (0.50) RXRARXRBRXRGNR4A2FFAR1
SCHEMBL3576699 0.84 PTPN1 (0.61) RXRARXRBRXRGNR4A2FFAR1
SCHEMBL16348239 0.84 MEN1 (0.65) RXRARXRBRXRGLTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257524-B1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS BRICKELL BIOTECH INC (US) 2016-01-06 EP disclosed
EP-2257524-B1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS BRICKELL BIOTECH INC (US) 2016-01-06 EP disclosed
CN-101952244-B N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors AMIRA PHARMACEUTICALS INC 2014-11-05 CN disclosed
CN-102076661-B Antagonists of prostaglandin d2 receptors AMIRA PHARMACEUTICALS INC 2014-04-09 CN disclosed
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2013-06-20 US disclosed
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2013-06-20 US disclosed
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2013-06-20 US disclosed
US-8362044-B2 N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-01-29 US disclosed
US-8362044-B2 N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-01-29 US disclosed
US-8362044-B2 N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-01-29 US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 US disclosed
EP-1585511-A4 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS AMGEN INC (US) 2007-08-29 EP disclosed
EP-1585511-A2 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS Tularik, Inc. (US) 2005-10-19 EP disclosed
US-20040220237-A1 Asthma and allergic inflammation modulators AMGEN INC. 2004-11-04 US disclosed
WO-2004058164-A2 ASTHMA AND ALLERGIC INFLAMMATION MODULATORS TULARIK, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158036-A1 N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 RXRA 767/4885RXRB 492/4885RXRG 403/4885
US-20080085891-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 RXRA 488/4885RXRB 451/4885RXRG 448/4885
US-20040220237-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 RXRA 488/4885RXRB 451/4885RXRG 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.